Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS

Alexandra C. Istl, Jessica M. Ruck, Carol D Morris, Adam Levin, Christian Meyer, Fabian Johnston

Research output: Contribution to journalReview article

Abstract

New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.

Original languageEnglish (US)
JournalJournal of Surgical Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Sarcoma
Meta-Analysis
Recurrence
Drug Therapy
Survival
Disease-Free Survival
Therapeutics

Keywords

  • chemotherapy
  • localized
  • resectable
  • soft tissue sarcoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{ffa42b7117de4b279dd43345a4437dd7,
title = "Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS",
abstract = "New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.",
keywords = "chemotherapy, localized, resectable, soft tissue sarcoma",
author = "Istl, {Alexandra C.} and Ruck, {Jessica M.} and Morris, {Carol D} and Adam Levin and Christian Meyer and Fabian Johnston",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jso.25401",
language = "English (US)",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Call for improved design and reporting in soft tissue sarcoma studies

T2 - A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS

AU - Istl, Alexandra C.

AU - Ruck, Jessica M.

AU - Morris, Carol D

AU - Levin, Adam

AU - Meyer, Christian

AU - Johnston, Fabian

PY - 2019/1/1

Y1 - 2019/1/1

N2 - New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.

AB - New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.

KW - chemotherapy

KW - localized

KW - resectable

KW - soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85061235303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061235303&partnerID=8YFLogxK

U2 - 10.1002/jso.25401

DO - 10.1002/jso.25401

M3 - Review article

C2 - 30737793

AN - SCOPUS:85061235303

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

ER -